Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 418-480-9 | CAS number: 138526-69-9 1-BROM-3,4,5-TRIFLUORBENZOL; 1-BROMO-3,4,5-TRIFLUOROBENZENE
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu./o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Acute Toxicity: inhalation
Administrative data
- Endpoint:
- acute toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- August 06, 1998 to September 24, 1998
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 998
- Report date:
- 1998
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 403 (Acute Inhalation Toxicity)
- Version / remarks:
- May 12, 1981
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.2 (Acute Toxicity (Inhalation))
- Version / remarks:
- December 29, 1992
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- acute toxic class method
- Limit test:
- yes
Test material
- Reference substance name:
- 1-bromo-3,4,5-trifluorobenzene
- EC Number:
- 418-480-9
- EC Name:
- 1-bromo-3,4,5-trifluorobenzene
- Cas Number:
- 138526-69-9
- Molecular formula:
- Hill formula: C6H2BrF3 CAS formula: C6H2BrF3
- IUPAC Name:
- 5-bromo-1,2,3-trifluorobenzene
- Test material form:
- liquid
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: RCC Ltd., Füllinsdorf, Switzerland
- Females nulliparous and non-pregnant: yes
- Age at study initiation: 7 – 9 weeks
- Weight at study initiation: 194 – 232 g
- Fasting period before study: no
- Housing: Groups of 5 per sex in type IV Makrolon cages
- Diet: ad libitum
- Water: ad libitum
- Acclimation period: 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 +/- 1
- Humidity (%): 46 – 86 %
- Photoperiod (hrs dark / hrs light): 12 / 12
IN-LIFE DATES: From days 1 - 15
Administration / exposure
- Route of administration:
- inhalation: vapour
- Type of inhalation exposure:
- nose only
- Vehicle:
- air
- Details on inhalation exposure:
- The test article was used as supplied by the Sponsor. A test atmosphere was generated in ambient conditions using a nebuliser connected to a syringe pump. Insertion of an aerosol-retaining filter before the exposure system facilitated exposure of the animals to the vapour phase of the test article only.
- Analytical verification of test atmosphere concentrations:
- yes
- Duration of exposure:
- 4 h
- Concentrations:
- 20 mg/L (nominal)
- No. of animals per sex per dose:
- 5 m / 5 f
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations: daily
- Frequency of weighing: days 1, 4, 8 and 15
- Necropsy of survivors performed: yes. The animals were examined macroscopically and any abnormalities would have been recorded. The lungs, trachea, larynx and the head containing the nasopharyngeal tissues were collected from all animals and fixed in neutral phosphate buffered 4 % formaldehyde solution. The lungs were instilled with the fixative at a hydrostatic pressure of 30 cm H2O. All collected organs/tissues are available for histopathological examinations, if requested by the Sponsor. - Statistics:
- Standard statistical methods have been applied for data processing.
Results and discussion
Effect levels
- Key result
- Sex:
- male/female
- Dose descriptor:
- LC50
- Effect level:
- > 22.23 mg/L air
- Exp. duration:
- 4 h
- Mortality:
- 0 / 5 m, 0 / 5 f
- Clinical signs:
- other: The principal clinical signs were the findings of decrease in locomotion activity, excitement and ruffled fur seen in all animals, whole-body tremor in two of five male and one of five female animals, and hunched posture in two of the male and all female
- Body weight:
- Transient, slight losses of body weight were evident in all animals from test day 1 (prior to exposure) to test day 4 (three days after exposure). Afterwards, all animals gained body weight normally.
- Gross pathology:
- Necropsy of each animal did not reveal any macroscopically findings.
Applicant's summary and conclusion
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- For regulatory purposes, the median lethal dose (LC50), after an observation period of 15 days can be declared as > 22.23 mg/L air.
- Executive summary:
The purpose of this GLP study performed according to OECD GL 403 was to assess the acute inhalation toxicity of the vapour phase of the test item when administered to rats for a single continuous 4-hour period at a target concentration of 20 mg/L air. Groups of five male and five female Albino Wistar rats were exposed by nose only, flow-past inhalation to the vapour phase of the test article at a mean concentration of 22.23 mg/L air. All animals were observed for clinical signs and mortality during and following the inhalation exposure over a 15-day observation period. Body weights were recorded prior to exposure on test day 1, and during the observation period on test days 4, 8, and 15. All animals underwent necropsy and any gross macroscopically changes would have been recorded.
There were no deaths. The principal clinical signs were the findings of decrease in locomotion activity, excitement and ruffled fur seen in all animals, whole-body tremor in two of five male and one of five female animals, and hunched posture in two of the male and all female animals. All of these findings, except that of excitement, were seen on the day of exposure and disappeared within one to four days afterwards. The finding of slight excitement occurred from two days after exposure (test day 3) until five days afterwards (test day 6). As from six days after exposure (test day 7) until the scheduled necropsy fourteen days afterwards (test day 15), all animals were free from clinical signs. Transient, slight losses of body weight were evident in all animals from test day 1 (prior to exposure) to test day 4 (three days after exposure). Afterwards, all animals gained body weight normally. Necropsy of each animal did not reveal any macroscopically findings.
The LC50 of the vapour phase of the test item was estimated to be greater than 22.23 mg/L air (analytical mean value).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)